Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake | Zendy

Carel W. le Roux | Zendy; Cynthia-Michelle Borg | Zendy; Kevin G. Murphy | Zendy; Royce P Vincent | Zendy; Mohammad A. Ghatei | Zendy; Stephen R. Bloom | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Supraphysiological doses of intravenous PYY_3-36 cause nausea, but no additional reduction in food intake

Author(s) -

Carel W. le Roux,

Cynthia-Michelle Borg,

Kevin G. Murphy,

Royce P Vincent,

Mohammad A. Ghatei,

Stephen R. Bloom

Publication year - 2008

Publication title -

annals of clinical biochemistry international journal of laboratory medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.6

H-Index - 80

eISSN - 1758-1001

pISSN - 0004-5632

DOI - 10.1258/acb.2007.007068

Subject(s) - nausea , appetite , peptide yy , medicine , food intake , endocrinology , neuropeptide , neuropeptide y receptor , receptor

Background Peptide YY (PYY 3-36 ) infused to levels within the physiological range reduces appetite and food intake in humans without nausea. However, PYY 3-36 has previously been shown to cause nausea at higher doses.Methods We studied the relationship of PYY 3-36 , nausea and food intake in six volunteers, using three different PYY 3-36 preparations infused to achieve supraphysiological PYY plasma levels.Results Supraphysiological levels of PYY caused nausea in five subjects ( P < 0.05). Although PYY 3-36 increased satiety ( P < 0.05) and reduced food intake ( P < 0.05), no greater enhancement of satiety or inhibition of food intake was observed compared with previous reports.Conclusions This study cautions against the use of supraphysiological doses of PYY 3-36 as it may increase nausea with no benefit in food reduction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research